[Nanoscale] Investigators screened several representative food-borne comparator engineered nanomaterials and reported that human colon cancer cells could insidiously exploit ZnO nanoparticle-induced adaptive response to acquire resistance against several chemotherapeutic drugs.
[International Immunopharmacology] Scientists discuss the beneficial effects of metformin on IBD using the results of in vitro, in vivo, and clinical studies.
[Journal of Hepatology] The spatial and temporal changes in hepatocytes and non-parenchymal cell types were validated by multiplex immunofluorescence staining, bulk transcriptomic sequencing, or flow cytometry.
[FEBS Journal] Hepatic Tipe1 deficiency decreased the level of reactive oxygen species in hepatocytes, which led to the inhibition of FoxO1 acetylation and LC3I to LC3II conversion, and p62 accumulation.
[Journal of Molecular Biology] Scientists test whether the deletion of a major lipid droplet protein alleviates fatty liver pathogenesis caused by alpha/beta hydrolase domain containing 5 deficiency in hepatocytes.
[Nature Reviews Gastroenterology & Hepatology] Expanding preclinical and clinical literature from PDAC and other oncological indications identifies novel approaches through which radiation therapy–immunotherapy combinations could improve local and systemic disease control in patients with PDAC.
[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.